Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
"Forza" is a non-specific trade name associated with several distinct pharmaceutical, veterinary, and nutraceutical products across international markets. In the context of biotechnology and human medicine, it primarily serves as a brand name for **teriparatide** (a recombinant human parathyroid hormone fragment PTH 1-34) used as an anabolic agent to treat osteoporosis, and **tadalafil** (a PDE5 inhibitor) used for erectile dysfunction and pulmonary arterial hypertension. Teriparatide, originally developed by Eli Lilly and marketed as Forza by Laboratorios Raffo, acts as an agonist at the Parathyroid Hormone Receptor 1 (PTH1R) to stimulate bone formation. Tadalafil, marketed as Forza by Lloyd Laboratories, increases cGMP levels to facilitate smooth muscle relaxation. Additionally, the name "Forza" is used for **nitenpyram**, a neonicotinoid insecticide marketed by Zydus for veterinary flea control, and **tenofovir disoproxil fumarate**, an antiretroviral used for HIV and Hepatitis B. In the United Kingdom, FORZA is also a prominent brand of dietary weight-loss supplements containing ingredients such as caffeine and acetyl-L-carnitine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Forza.